预约演示

NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization

2024-07-10

交易

高管变更临床2期孤儿药

PARAMUS, N.J., July 10, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that its Board of Directors has appointed a new President at its US headquarters. Yukiteru Sugiyama, Ph.D. replaces retiring president Tsugio Tanaka, MSc as of June 30, 2024.

"As president, it is my mission to maintain heightened levels of empathy at NS Pharma."

Post this

Yukiteru Sugiyama, PhD, NS Pharma President

Sugiyama received a doctNS Pharmaree in organic chemistry from Nagoya University in 1996. From 1996 until 2007, he worked in research and clinical development with Nippon Shinyaku in Japan, focusing on structural chemistry and blood cancer therapies. In 2007, he transitioned to the commercial division within the company.

In 2020, during the COVID-19 pandemic, Sugiyama transferred to Nagoya UniversityUS to work as assistant vice president overseeing commercial functions for VILTEPSO®Nippon ShinyakuIn total, Sugiyama has worked for 28 years at Nippon Scanceru with progressive levels of responsibility.

"Having served in boCOVID-19 pandemicd patient focused fields, NS Pharmame to understand that having empathy for the patient is critical in the developmentVILTEPSOapviltolarsent rare diseases," Sugiyama explained. "As presideNippon Shinyakussion to maintain heightened levels of empathy at NS Pharma, and to enhance transparency between all stakeholders."

Sugiyama will lead the company through the next phases of clinical and commercial development for VILTEPSO and CAP-1002 (through a partnership with Capricor Therapeutics) – for the treatment of Duchenne muscular dystrophy (Duchenne). NS Pharma is also currently working on an exon 44 skippiNS Pharmay (Phase 2) and an exon 50 skipping therapy (Phase 1/2) for Duchenne, a selective JAK1 inhibition therapy for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), as well as several preclinical neurological therapies.

Sugiyama Pharma, Inc.VILTEPSO CAP-1002 Capricor Therapeutics Duchenne muscular dystrophy (Duchenne)NS Pharma exon 44 JAK1 eosinophilic granulomatosis with polyangiitis (EGPA)

NS PhaNS Pharma, Inc. wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.